LabCorp Beats, Raises EPS Guidance - Analyst Blog
April 21 2011 - 10:08AM
Zacks
Leading lab-testing company
Laboratory Corporation of America Holdings (LH)
reported adjusted EPS of $1.52 (excluding amortization,
restructuring and other special charges) for the first quarter of
fiscal 2011.
That was way above the Zacks
Consensus Estimate of $1.44 and the previous year's adjusted EPS of
$1.40.
Moreover, severe weather had a
negative impact of 8 cents on the EPS.
Revenues increased 14.6% year over
year to $1,368.4 million, ahead of the Zacks Consensus Estimate of
$1,325 million. Testing volume (measured by requisitions) and
revenue per requisition increased 5.9% and 8.2%, respectively.
Results for the reported quarter include the operations of Genzyme
Genetics, acquired in the fourth quarter of 2010.
Gross margin during the quarter
declined 100 basis points to 41.5%. Moreover, a 15% rise in
selling, general and administrative expenses led to a 110-basis
point decline in adjusted operating margin to 19.3%. LabCorp’s
interest expense increased 64% during the quarter due to higher
debt burden.
The company had raised $925 million
in November 2010, primarily to fund the acquisition of Genzyme
Genetics. With the acquisition of Genzyme Genetics, LabCorp expects
to strengthen its esoteric testing and personalized medicines
business.
LabCorp exited the quarter with
cash and short-term investments of $195.4 million, compared to
$230.7 million at the end of December 2010. During the quarter, the
company repurchased 2.9 million shares for $265 million and was
left with $469 million of authorization.
Outlook
LabCorp reiterated its revenue
guidance (9.5%-11.5% growth) for fiscal 2011. However, it raised
its adjusted EPS guidance to $6.17−$6.32 (previous guidance of
$6.12-$6.32). In addition, operating cash flow and capital
expenditure is expected to be $900 million and within $140-$150
million, respectively.
Recommendation
LabCorp continues to focus on
strategic initiatives to drive growth and profitability. It
includes introduction of innovative tests in the genomic/esoteric
arena (specifically in the area of cancer), a greater focus on
managed care organizations, and aggressive penetration into the
hospital market. The company is focusing more on the high margin
esoteric testing business, and has set a target of recording 45% of
its revenues from this specialty business in the next 3-5
years.
However, the tough competitive
landscape is of primary concern, and the leading diagnostic players
are all striving for a greater share in the high margin,
specialized testing business. In this regard, Quest
Diagnostics (DGX) recently acquired Athena Diagnostics,
which is involved in diagnostic tests for neurological conditions,
and is also in the process of acquiring Celera
Corp (CRA).
We currently have a Neutral
recommendation on the stock, which also corresponds to the Zacks #3
Rank (Hold).
CELERA CORP (CRA): Free Stock Analysis Report
QUEST DIAGNOSTC (DGX): Free Stock Analysis Report
LABORATORY CP (LH): Free Stock Analysis Report
Zacks Investment Research
Celera Corp. (MM) (NASDAQ:CRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celera Corp. (MM) (NASDAQ:CRA)
Historical Stock Chart
From Apr 2023 to Apr 2024